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Abstract: Background: Early identification of AMD can lead to prompt and more effective treatment,
better outcomes, and better final visual acuity; several risk scores have been devised to determine
the individual level of risk for developing AMD. Herein, the Delphi method was used to provide
recommendations for daily practice regarding preventive measures and follow-up required for
subjects at low, moderate, and high risk of AMD evaluated with the Simplified Test AMD Risk-
assessment Scale (STARS®) questionnaire. Methods: A steering committee of three experts drafted
and refined 25 statements on the approach to be recommended in different clinical situations [general
recommendations (n = 2), use of evaluation tools (n = 4), general lifestyle advice (n = 3), and AREDS-
based nutritional supplementation (n = 5)] with the help of a group of international experts, all
co-authors of this paper. Thirty retinal specialists from Europe and the US were chosen based on
relevant publications, clinical expertise, and experience in AMD, who then provided their level of
agreement with the statements. Statements for which consensus was not reached were modified and
voted upon again. Results: In the first round of voting, consensus was reached for 24 statements.
After modification, consensus was then reached for the remaining statement. Conclusion: An
interprofessional guideline to support preventive measures in patients at risk of AMD based on
STARS® scoring has been developed to aid clinicians in daily practice, which will help to optimize
preventive care of patients at risk of AMD.
Keywords: age-related macular degeneration; prevention; identification; risk; Delphi; STARS®;
food supplement
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1. Introduction
Age-related macular degeneration (AMD) is a primary reason for blindness in Western
countries [1–3]. The number of individuals with AMD is believed to rise globally by
around 40% from 2020 to 2040, highlighting the need for effective preventive measures
and therapies [2]. The two late phenotypes of AMD, neovascular and atrophic AMD, are
usually preceded by drusen and pigmentary abnormalities.
Considerable progress has been made in the treatment of AMD, and in this regard,
intravitreal injections of antiangiogenic agents have greatly changed the management
of neovascular AMD [3]. While these agents can provide stabilization or even rapid
improvement of visual acuity in the majority of patients at the start of treatment, the long-
term results regarding visual acuity and quality of life remain uncertain [4–6]. Moreover,
there is still no therapy for geographic atrophy, which represents a considerable proportion
of cases of late AMD. This confirms that despite therapeutical progress, late-stage AMD
remains a major cause of visual loss. Early identification of patients at risk of AMD is thus
of significant clinical relevance, as it can lead to more effective treatment, better outcomes,
and better visual acuity [7].
Epidemiological studies have unveiled the existence of several risk factors for AMD,
which include smoking, diet, family history of AMD, and cardiovascular disease, as
well as both clinical and ocular risk factors. Several of these risk factors have shown
strong associations with AMD (especially smoking, ethnicity, and family history of AMD),
although for others such as gender and iris color the results have been less consistent [3,8,9].
In addition, more than 50 genetic polymorphisms have been identified that contribute to
the disease [9,10].
Conversely, many endogenous and exogenous micronutrients have been implicated
in the protection of the retina against AMD through different mechanisms including
antioxidant, anti-inflammatory, and blue light absorption [9,11–18]. Animal models and
cell culture studies have suggested that oxidative stress to the retina is an important
factor contributing to AMD, and large interventional studies have shown that antioxidant
nutrients given as supplements appear to exert a protective effect against progression to
advanced forms of AMD [18–22]. Altogether, it is now generally accepted that adequate
intake of micronutrients is crucial for a healthy retina and vitamin supplementation needs
to be considered in the management of patients with late-stage or progressing AMD [23–27].
Early identification of AMD is of significant clinical relevance, as it can lead to prompt
and more effective treatment, better outcomes, and better final visual acuity [7]. In this
regard, risk scores have been devised to establish the risk for AMD, thereby allowing for
individualized management [28–35]. Even if some of these models have good discrimina-
tion for AMD, most include assessment of genetic polymorphisms, which are not used on a
routine basis in clinical practice. While clinical, lifestyle, and ocular risk factors have been
related to AMD, few risk scores have included dietary considerations [14,29,31–33].
Given the need for early identification of individuals at risk and improving disease out-
comes, an easy to compile self-administered 13-item questionnaire to evaluate individual
risk for AMD in daily practice has been developed (Simplified Test AMD Risk-assessment
Scale—STARS®) [36]. The scoring system was derived from an initial sample of 12,639 Ital-
ian subjects and subsequently validated on 6897 French subjects. The questionnaire showed
good discrimination, allowing stratification of subjects according to the risk of AMD (low,
moderate, high). The translational relevance of the STARS® score in predicting macular
function in early and intermediate AMD has been recently pointed out: STARS® is able
to predict central retinal function with a high degree of accuracy, as assessed by full-field
electroretinogram, which suggests that both parameters can be combined to assess the
clinical risk for loss of visual function even in the early disease stages [37].
Following the development and validation of the score, a process was activated to
develop specific recommendations regarding the preventive measures and ophthalmolog-
ical follow-up to adopt, tailored according to the individual level of risk for AMD that
can complement existing guidelines. This is also important considering that validated
J. Clin. Med. 2021, 10, 5432 3 of 12
recommendations can help ophthalmologists to individualize consultations with patients
and save time.
Herein, the Delphi method [38] has been used to provide recommendations for the
preventive measures to adopt in individuals at low, moderate, and high risk of AMD based
on STARS®.
2. Materials and Methods
2.1. Delphi Process
The consensus process was carried out with a three-step Delphi method [39,40]. The
Delphi method has been used in healthcare settings as a good means of obtaining consen-
sus [38,41–45]. The method is a consecutive process that uses repeated rounds of voting
and is effective in obtaining expert consensus for which there is limited evidence [42].
The overall Delphi process adopted is summarized in Figure 1. In March 2019, in the
first step, a steering committee composed of three experts drafted a series of statements
through a web-based meeting. The scientific committee, a group of international experts
and co-authors of this paper, then further refined the statements until final approval of a
list of 25 statements, regarding the best approach to recommend in patients with diverse
levels of risk for developing AMD based on STARS® score (low, score 0–9; moderate, score
10–19; high, score ≥ 20), age (50–70 years, >70 years) and AREDS categories [46]. STARS®
is based on patient data (age, sex, and ethnicity), family history of AMD, medical history,
and eye characteristics [36].
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Figure 1. Overview of Delphi process used.
For the second step of the Delphi process, retinal specialists from across Europe and
the US were chosen based on relevant publications, clinical expertise in the retina, and
experience in AMD. Thirty retinal experts were contacted via email and asked to take
part in the consensus project, and 24 participants (75%) agreed to participate (France, 2;
Spain, 4; UK, 3; Germany, 1; Portugal, 2; Russia, 3; Ukraine, 1; Italy, 2; Poland 2; Turkey,
2; Belgium, 1; USA, 1). The first round of voting took place in July 2019 via a dedicated,
password-protected online platform. The steering committee analyzed the results of voting
and modified the statements for which agreement was not obtained, based on feedback
from the participants. The second round of voting took place in January 2020.
2.2. Analysis of Voting and Determination of Agreement
Participants were requested to rate their agreement with the statements proposed on
a scale from 1 to 9, where 1 is complete disagreement and 9 is complete agreement. Ratings
of 1–3 were classified as disagreement, while ratings of 7–9 were classified as agreement.
Ratings of 4–6 were classified as neutral.
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Disagreement was assessed as follows. First, the value of inter-percentile range (IPR)
was calculated, i.e., the range of responses between the 70th and the 30th percentiles. Next,
the value of the inter-percentile range adjusted for symmetry (IPRAS) was calculated,
which assesses dispersion for asymmetric distributions; finally, the values of IPR and
IPRAS were calculated. Disagreement was considered when IPR > IPRAS [46].
Disagreement inevitably produced an uncertain decision. If, on the other hand, there
was no disagreement, the median determined if the agreement was positive, negative, or
uncertain. If the median was from 7–9, then a positive is obtained, and the statement was
considered relevant for the management of AMD. If the median was from 1–3, then the
decision was negative, and the statement was not considered relevant for the management
of AMD. A median that was within the 4–6 range produced an uncertain decision.
2.3. Ethics Approval
No formal ethics approval was required. All participants agreed to participate, and
the data are presented at the group level only. As such, it is not possible to identify an
individual participant.
3. Results
The Steering Committee, with the help of the scientific committee, all co-authors of
this paper, drafted a total of 25 statements in different areas, comprising general recom-
mendations (n = 2), use of evaluation tools (n = 4), general lifestyle advice (n = 3), and
AREDS-based nutritional supplementation (n = 5) (Table 1). In addition, five statements
were proposed for subjects at moderate risk of AMD, and six statements for those at high
risk (Table 2). Each Delphi panel expert then voted on his/her level of agreement with
each statement using an online platform. Participants had no access to the decisions of
the other experts. Consensus, considered when IPR < IPRAS, was reached for 24 of the
25 statements in the first round of voting for statements involving general issues, evaluation
tools, lifestyle advice, and AREDS-based nutritional supplementation.
Table 1. Consensus statements on general issues, evaluation tools, general lifestyle advice, and AREDS-based supplementa-
tion.
General Recommendations IPR IPRAS Median Consensus
1 Intravitreal injections are the first-choice treatment forpatients with wet AMD to stop progression of the disease 0 15.0 9.0 Positive agreement
2
Patients at high risk of AMD should receive nutritional
supplements to help reduce the risk of progression at an
early phase after diagnosis of AMD
2.2 10.9 9.0 Positive agreement
Evaluation tools
3 Early detection with simple tools is desirable to detectpatients at risk of AMD and treat promptly if needed 0 15.0 9.0 Positive agreement
4 The STARS
® questionnaire is a valid tool to assess risk of
AMD in the general population
1 9.4 8.0 Positive agreement
5
Stratification according to risk of AMD is useful in order to
plan lifestyle interventions, give dietary advice and plan
follow-up using STARS® and the AREDS category score
1 13.1 8.0 Positive agreement
6
Ophthalmologists should use the STARS® and AREDS
classifications in daily practice to evaluate the risk of AMD
and to define the best prevention strategy and follow-up
for patients
2 11.3 8.0 Positive agreement
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Table 1. Cont.
General Recommendations IPR IPRAS Median Consensus
General lifestyle advice
7
All subjects at risk of AMD should be advised to stop
smoking, adopt a Mediterranean diet, and carry out
regular physical activity
0 15.0 9.0 Positive agreement
8
Increased intake of vegetables, fruit and fish should be
actively encouraged in the aging population as <4% of
individuals ≥ 55 years of age achieve adequate intake of
these food groups
1 13.1 9.0 Positive agreement
9
If patients are unable or unwilling to follow a
Mediterranean diet, nutritional supplements should be
recommended in subjects at high risk of AMD
2 11.3 9.0 Positive agreement
AREDS-based supplementation
10 An AREDS-based formulation significantly reduces therisk of developing advanced AMD in the long-term 2 11.3 8.0 Positive agreement
11 An AREDS-based formulation decreases the overall risk ofmoderate vision loss in the long term 2 11.3 8.0 Positive agreement
12A
An AREDS-based formulation has no significant benefit on
the progression of dry AMD or development of geographic
atrophy in the long term
4.5 0.9 5.0 No agreement
12B
An AREDS-based formulation may have benefit on the
progression of dry AMD or development of geographic
atrophy in the long term
3 5.6 7.0 Positive agreement
13
The best-validated supplementation therapy for patients
suffering from AMD with geographic atrophy without
central involvement of the fovea is an
AREDS-based formulation
3.5 4.7 7.0 Positive agreement
14
Initiating supplementation with an AREDS-based
formulation in patients at high risk of AMD is more cost
effective than no use of supplements and should
be advocated
2 11.3 8.0 Positive agreement
Table 2. Consensus statements for subjects with moderate and high risk of developing AMD.
Moderate Risk Subjects (STARS® 10–19) IPR IPRAS Median Consensus
15
Moderate risk subjects according to STARS® (STARS®
score 10–19) and with AREDS category 2 and
55–70 years of age should be asked to carry out
self-monitoring (e.g., with Amsler grid)
2.5 10.3 7.5 Positive agreement
16
Moderate risk subjects according to STARS® (STARS®
score 10–19) and with AREDS category 2 and
55–70 years should have follow-up every 2 to 3 years
3 3.8 6.5 Uncertain relevance
17
Moderate risk subjects according to STARS® (STARS®
score 10–19) and with AREDS category 2 and
age > 70 years should be asked to carry out
self-monitoring (e.g., with Amsler grid).
2 11.3 8.0 Positive agreement
18
Moderate risk subjects according to STARS® (STARS®
score 10–19) and with AREDS category 2 and
age > 70 years should be recommended specific
nutritional supplements for prevention of AMD
2.5 10.3 8.0 Positive agreement
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Table 2. Cont.
Moderate Risk Subjects (STARS® 10–19) IPR IPRAS Median Consensus
19
Moderate risk subjects according to STARS® (STARS®
score 10–19) with AREDS category 2 and age > 70 years
should have annual follow-up
2 11.3 9.0 Positive agreement
High risk subjects (STARS® ≥ 20)
20
High risk subjects according to STARS®
(STARS® ≥ 20), with AREDS category 1 and
55–70 years of age should be asked to carry out
self-monitoring (e.g., with Amsler grid)
2.5 10.3 8.0 Positive agreement
21
High risk subjects according to STARS®
(STARS® ≥ 20), with AREDS category 1 and
age > 70 years should be asked to carry out
self-monitoring
3 9.4 8.0 Positive agreement
22
High risk subjects according to STARS®
(STARS® ≥ 20), with AREDS category 1 and
age > 70 years should be recommended specific
nutritional supplements for prevention of AMD
3 9.4 8.0 Positive agreement
23
High risk subjects according to STARS®
(STARS® ≥ 20), with AREDS category 2, aged 55 years
or more, should be asked to carry out self-monitoring
(e.g., with Amsler grid)
1.5 12.2 8.0 Positive agreement
24
High risk subjects according to STARS®
(STARS® ≥ 20), with AREDS category 2, aged 55 years
or more, should be recommended specific nutritional
supplements for prevention of AMD
2 11.3 8.0 Positive agreement
25
High risk subjects according to STARS® (STARS® ≥ 20)
with AREDS category 2, independently of age, should
have follow up every 6 months
4.5 4.7 7.0 Positive agreement
In the first round of voting, consensus (IPR < IPRAS) was reached for all statements,
except for statement 12, which had IPR > IPRAS and reached a median of 5 in voting
(Table 1, statement 12A). This statement had been initially worded as “An AREDS-based
formulation has no significant benefit on the progression of dry AMD or development of
geographic atrophy in the long term”. While some experts commented that more evidence
is needed, others said that there is sufficient data to recommend the use of an AREDS-based
formulation in dry AMD. Based on this, the statement was reworded as “An AREDS-
based formulation may have benefit on the progression of dry AMD or development of
geographic atrophy in the long term”. After a second round of voting, in which 19 (79%)
Delphi panel experts participated, consensus was reached for this reworded statement (12B
in Table 1). Eventually, all statements received positive agreement (median ≥ 7), except for
statement 16 which was judged of uncertain relevance (median of votes 6.5).
4. Discussion
The present Delphi consensus had the main objective of formulating a series of vali-
dated recommendations on ophthalmological follow-up and preventive measures to adopt
for subjects with a low, moderate, and high risk of developing AMD evaluated with the
STARS® questionnaire, which can be useful for ophthalmologists in daily practice. The Del-
phi process was chosen with the aim of obtaining a consensual response from international
panel of experts as there is limited evidence available [43]. While absolute agreement is
rarely obtained, the Delphi methodology helps to identify a group consensus [43]. Con-
sensus was reached for 24 of the 25 statements proposed in the first round of voting. The
results of voting for each of the three main areas are discussed below.
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4.1. General Recommendations
Statement #1 addressed the use of intravitreal injections as the first choice in the
treatment of patients with wet AMD to stop disease progression as supported by expert
recommendations following diagnosis of choroidal neovascularization (CNV) [47], and
fully recommended by the European Society of Retina Specialists (EURETINA) [48]. Some
of the experts commented that the utility of intravitreal injections is not only to halt the
progression of the disease, but also to increase visual acuity and quality of life as much
as possible.
Statement #2 addressed the use of nutritional supplements at an early phase of AMD
to help reduce the risk of progression in patients at a high risk of AMD. Indeed, there is
now general agreement that the positive effects of the AREDS1 and AREDS2 formulations
are a result of their antioxidant properties [49], and, based on the AREDS studies, a number
of dietary supplements are currently available. Such formulations, in addition to the diet
and healthy lifestyle recommendations below, are now considered to be the standard of
care to reduce the risk of reaching advanced AMD among those with an elevated risk of
progressing to severe visual loss [50].
4.2. Use of Evaluation Tools
Early identification of high-risk subjects using a simple tool is a highly desirable goal
such that appropriate subjects can be offered ophthalmological follow-up (especially for
early diagnosis and treatment of neovascular AMD, as needed) (Statement #3). Moreover,
the STARS® questionnaire was considered to be a valid tool to assess the risk of AMD
in the general population (statement #4). STARS® is a simple and easy-to-use 13-item
questionnaire based on the presence of risk factors auto-administered by patients [36]. The
STARS® questionnaire has been validated in two large European observational cohorts and
shows good discrimination of risk of AMD into low, moderate, and high-risk categories [36].
As such, STARS® would appear to meet the ideal criteria for a simple screening tool for
daily practice.
It was further held that stratification according to the risk of AMD is useful in order
to plan lifestyle interventions, give dietary advice, and plan ophthalmological follow-up
using STARS® and the AREDS category score (statement #5). Both scoring systems provide
simple risk categories and are complementary since the AREDS classification relies only on
retinal alterations identified at clinical examination, while the STARS® score relies only on
an auto-administered evaluation of risk factors [46]. Several recent studies have indicated
that consumption of a Mediterranean diet appears to offer some benefits against developing
AMD, possibly through increased intake of micronutrients and antioxidants [14,15,51,52].
In addition, physical activity and weight control are receiving increased attention for
their possible role in the prevention of AMD [27]. The last statement on evaluation tools
considered that ophthalmologists should use the STARS® and AREDS category score in
daily practice to evaluate the risk of AMD and to define the best prevention strategy and
follow-up (statement #6). This recommendation is based on the above considerations.
4.3. General Lifestyle Advice
Consensus was reached for all the statements on general lifestyle advice, advocating
that all subjects who are at risk for AMD should stop smoking, adopt a Mediterranean diet,
and carry out regular physical activity (statement #7) as documented in the literature [9,14,
15,27,52,53]. In addition, increased intake of vegetables, fruit and fish should be actively
encouraged in the aging population, considering that <4% of individuals ≥ 55 years of
age had adequate intake of these food groups in an epidemiological study performed in
the Netherlands (statement #8) [17,54]. The benefits of dietary omega-3 fatty acid and
fish intake in reducing the risk of AMD, for example, appear to be well consolidated as
demonstrated by several studies and summarized in a meta-analysis by Chong et al. [55].
This is in contrast to the unexpected, negative results of the AREDS2 study in terms of the
benefits of omega-3 fatty acids and AMD [19]. Possible explanations for this, as noted by
J. Clin. Med. 2021, 10, 5432 8 of 12
other authors, include the complex study design. AREDS2 subjects were already taking
AREDS1 supplements, which together with the lack of a placebo group for comparison,
may not have allowed for the effects of omega-3 fatty acids to be sufficiently evident [18].
Furthermore, smoking is considered to be an important modifiable risk factor for
the development and progression of AMD [56,57]. All patients at risk should therefore
be actively encouraged to stop smoking. The last statement on general lifestyle advice
considered that if patients are unable or unwilling to follow a diet rich in green leafy
vegetables, fruits, and fish, such as the Mediterranean diet, nutritional supplements should
be recommended in subjects at high risk of AMD (statement #9).
4.4. AREDS-Based Supplementation
There were five statements on AREDS-based supplementation. The experts considered
that a nutritional formulation reduces the risk of developing advanced AMD in the long-
term (statement #10) and that it decreases the overall risk of moderate vision loss in the
long term (statement #11). Statement #12A was initially worded as “An AREDS-based
formulation has no significant benefit on the progression of dry AMD or development of
geographic atrophy in the long term”, for which agreement was not reached. The statement
was then modified to “An AREDS-based formulation may have benefit on the progression
of dry AMD or development of geographic atrophy in the long term”, and after a second
round of voting, agreement was reached.
The Age-Related Eye Disease Study (AREDS)-2 study showed that supplementation
with antioxidant nutrients decreases the risk of progression to neovascular AMD [19,58].
The potential benefit of AREDS-based supplementation is also based on several clinical
trials with individual supplements [18,22,59,60], and reviewed in [50]. In fact, for many
years before AREDS, micronutrition was held to be an integral part of routine management
of AMD [17,23]. Moreover, nutritional strategies for secondary prevention of AMD are
present in virtually all clinical guidelines [61].
The experts also considered that the best-validated supplementation therapy for pa-
tients suffering from AMD with geographic atrophy without central involvement of the
fovea is an AREDS-based formulation (statement #13). The last statement on AREDS-based
supplementation (#14) held that initiating a supplementation with an AREDS-based for-
mulation in patients at high risk of AMD is more cost effective than no use of supplements
and should be advocated. This is largely based on the real-world study by Lee et al. in
the UK, wherein initiating AREDS-based supplements in AREDS category 4 patients was
found to be both cost-effective and superior to no use of supplements [26].
4.5. Moderate and High-Risk Subjects
The remaining statements (#15–25) involved recommendations for monitoring, nutri-
tion, and follow-up in subjects with moderate (STARS® 10–19) and high (STARS® ≥ 20) risk
for AMD. Subjects with moderate risk, AREDS category 2, and 55–70 years of age should
be asked to carry out self-monitoring (statement 15) and have follow-up every 2–3 years
(statement 16), although the recommendation on follow-up frequency was considered of
uncertain relevance. The lengthy follow-up time was made in consideration of the low risk
of progression at 5 years, although for some panelists it was held that follow-up might be
more frequent and that any patient at risk should be asked to carry out self-monitoring.
Those with the same risk profile but with age > 70 years should carry out self-monitoring,
be recommended specific nutritional supplements, and have annual follow-up (statements
17–19). Some participants felt that even stricter follow-up might be applied in some cases.
The statements for high-risk subjects (STARS® ≥ 20) were divided into those with
AREDS category 1 or 2. All subjects with high-risk and with either AREDS category
1 or 2 over the age of 55 should be asked to carry out self-monitoring (statements 20,
21, and 23). High-risk subjects with AREDS category 1 over the age of 70 should be
recommended to take specific nutritional supplements (statement 22), as should high-risk
subjects with AREDS category 2 over the age of 55 years (statement 24). Independently of
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age, high-risk subjects with AREDS category 2 should undergo follow-up every 6 months.
It was, however, noted that a prospective randomized trial would be needed to confirm the
utility of these recommendations in this group of subjects. Lastly, it should be highlighted
that these recommendations are broadly in line with those issued by several national
societies, such as the American Optometric Association, EURETINA [48], NICE [62], and
the American Academy of Ophthalmology [63].
The Delphi methodology is a well-known process that aids in achieving group consen-
sus. An advantage of our methodology is the online procedure adopted. During the two
rounds carried out online, response rates were high with copious feedback, in line with a
previous report [64].
At the same time, the limitations of the Delphi process warrant comment. First, given
the internet-based nature of the present study, the panel members were unable to directly
discuss specific wording of the statements. Moreover, the success of the Delphi process
is further dependent on the panel selected to participate. While there are no established
criteria to select experts and no specific guidance regarding the number of participants, we
made a concerted effort to obtain a representative distribution of experts across several
countries. The high level of consensus achieved suggests that these limitations are minimal.
5. Conclusions
In the present Delphi consensus, statements to support preventive measures in patients
at risk of AMD based on STARS® scoring were developed. The recommendations deliver
the means to optimize preventive care for patients in different geographical regions. It is
hoped that the statements developed will be of benefit to clinicians in daily practice. This
is especially relevant given that a proportion of ophthalmologists do not always properly
counsel patients on the lifestyle changes to adopt, and, likewise, patients do not always
adhere to specific recommendations. Future work should involve translating guidelines
into routine clinical practice followed by evaluating their impact on the care of patients.
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